Oligonucleotide therapeutics in sports? An antidoping perspective

Maria K. Parr,Annekathrin M. Keiler

DOI: https://doi.org/10.1002/ardp.202400404

2024-10-26

Archiv der Pharmazie

Abstract:Several gene therapies including oligonucleotide therapeutics have been approved during the last 20 years. In sports, the use of nucleic acids or nucleic acid analogs is prohibited. This review discusses types of oligonucleotide therapeutics, their potential to be misused in sports, and considerations to sample preparation and mass spectrometric approaches with regard to antidoping analysis. Within the last two decades, the European Medicines Agency and the US Food and Drug Administration have approved several gene therapies. One category is oligonucleotide therapeutics, which allow for the regulation of the expression of target genes. Besides already approved therapeutics, there are several preclinical and clinical trials ongoing. The World Anti‐Doping Agency prohibits the use of "nucleic acids or nucleic acid analogs that may alter genome sequences and/or alter gene expression by any mechanism" as a nonspecified method at all times. Hence, the administration of nucleic acids or analogs by athletes would cause an Anti‐Doping Rule Violation. Herein, we discuss types of oligonucleotide therapeutics, their potential to be misused in sports, and considerations to sample preparation and mass spectrometric approaches with regard to antidoping analysis.

pharmacology & pharmacy,chemistry, medicinal, multidisciplinary